CL2022002692A1 - Derivados de n-(heterociclil y heterociclilalquil)-3-bencilpiridin-2-amina como agonistas de sstr4 - Google Patents
Derivados de n-(heterociclil y heterociclilalquil)-3-bencilpiridin-2-amina como agonistas de sstr4Info
- Publication number
- CL2022002692A1 CL2022002692A1 CL2022002692A CL2022002692A CL2022002692A1 CL 2022002692 A1 CL2022002692 A1 CL 2022002692A1 CL 2022002692 A CL2022002692 A CL 2022002692A CL 2022002692 A CL2022002692 A CL 2022002692A CL 2022002692 A1 CL2022002692 A1 CL 2022002692A1
- Authority
- CL
- Chile
- Prior art keywords
- benzylpyridin
- heterocyclylalkyl
- heterocyclyl
- amine derivatives
- sstr4
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se describen compuestos de la Fórmula 1 y sales farmacéuticamente aceptables de estos, en donde n, R1, R4, R5, R6, R7, R8, R9, R10, R11, R14, X2, X3 y X12 se definen en la memoria descriptiva. Esta descripción también hace referencia a materiales y métodos para la preparación de compuestos de la Fórmula 1, a composiciones farmacéuticas que los contienen, y a su uso para el tratamiento de enfermedades, trastornos y afecciones asociados con SSTR4.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063002623P | 2020-03-31 | 2020-03-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2022002692A1 true CL2022002692A1 (es) | 2023-06-16 |
Family
ID=75660334
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2022002692A CL2022002692A1 (es) | 2020-03-31 | 2022-09-30 | Derivados de n-(heterociclil y heterociclilalquil)-3-bencilpiridin-2-amina como agonistas de sstr4 |
Country Status (17)
Country | Link |
---|---|
US (1) | US20230192659A1 (es) |
EP (1) | EP4126849A1 (es) |
JP (1) | JP2023520006A (es) |
KR (1) | KR20220161437A (es) |
CN (1) | CN115485273B (es) |
AR (1) | AR121682A1 (es) |
AU (1) | AU2021249109A1 (es) |
BR (1) | BR112022019583A2 (es) |
CA (1) | CA3178347A1 (es) |
CL (1) | CL2022002692A1 (es) |
CO (1) | CO2022014111A2 (es) |
EC (1) | ECSP22082219A (es) |
IL (1) | IL296602A (es) |
MX (1) | MX2022012225A (es) |
PE (1) | PE20230740A1 (es) |
TW (1) | TW202204342A (es) |
WO (1) | WO2021202775A1 (es) |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
JO2952B1 (en) * | 2005-08-03 | 2016-03-15 | جانسين فارماسوتيكا ان. في | Quinoline derivatives acting as antibacterial agents |
AU2010313392B2 (en) * | 2009-10-30 | 2015-07-09 | Janssen Pharmaceutica Nv | Pyrazines as delta opioid receptor modulators |
TWI834637B (zh) * | 2018-03-01 | 2024-03-11 | 日商武田藥品工業有限公司 | 六氫吡啶基-3-(芳氧基)丙醯胺及丙酸酯 |
-
2021
- 2021-03-29 AR ARP210100774A patent/AR121682A1/es unknown
- 2021-03-31 JP JP2022559767A patent/JP2023520006A/ja active Pending
- 2021-03-31 TW TW110111867A patent/TW202204342A/zh unknown
- 2021-03-31 CN CN202180032351.9A patent/CN115485273B/zh active Active
- 2021-03-31 CA CA3178347A patent/CA3178347A1/en active Pending
- 2021-03-31 PE PE2022002165A patent/PE20230740A1/es unknown
- 2021-03-31 WO PCT/US2021/025225 patent/WO2021202775A1/en active Application Filing
- 2021-03-31 EP EP21721279.4A patent/EP4126849A1/en active Pending
- 2021-03-31 MX MX2022012225A patent/MX2022012225A/es unknown
- 2021-03-31 US US17/916,476 patent/US20230192659A1/en active Pending
- 2021-03-31 KR KR1020227037817A patent/KR20220161437A/ko unknown
- 2021-03-31 IL IL296602A patent/IL296602A/en unknown
- 2021-03-31 BR BR112022019583A patent/BR112022019583A2/pt unknown
- 2021-03-31 AU AU2021249109A patent/AU2021249109A1/en active Pending
-
2022
- 2022-09-30 CO CONC2022/0014111A patent/CO2022014111A2/es unknown
- 2022-09-30 CL CL2022002692A patent/CL2022002692A1/es unknown
- 2022-10-28 EC ECSENADI202282219A patent/ECSP22082219A/es unknown
Also Published As
Publication number | Publication date |
---|---|
BR112022019583A2 (pt) | 2022-12-06 |
EP4126849A1 (en) | 2023-02-08 |
MX2022012225A (es) | 2022-10-27 |
ECSP22082219A (es) | 2022-12-30 |
AR121682A1 (es) | 2022-06-29 |
CA3178347A1 (en) | 2021-10-07 |
PE20230740A1 (es) | 2023-05-03 |
AU2021249109A1 (en) | 2022-10-20 |
CN115485273B (zh) | 2024-08-13 |
JP2023520006A (ja) | 2023-05-15 |
US20230192659A1 (en) | 2023-06-22 |
CN115485273A (zh) | 2022-12-16 |
IL296602A (en) | 2022-11-01 |
CO2022014111A2 (es) | 2022-12-30 |
TW202204342A (zh) | 2022-02-01 |
WO2021202775A1 (en) | 2021-10-07 |
KR20220161437A (ko) | 2022-12-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NI202000078A (es) | Compuestos heteroaril tetracíclicos | |
UY38602A (es) | Compuestos tricíclicos condensados | |
NI201900039A (es) | Derivados de 6, 7, 8, 9-tetrahidro-3h-pirazolo[4, 3-f] isoquinolina útiles en el tratamiento del cáncer | |
ECSP20062464A (es) | Piperidinil-3-(ariloxi)propanamidas y propanoatos | |
CL2020002562A1 (es) | (divisional de solicitud 1097-2020) derivados de piridincarbonilo y usos terapéuticos de los mismos como inhibidores de trpc6. | |
PA8490601A1 (es) | Derivados quinolin-2-ona sustituidos con heteroarilo utiles como agentes anticancerigenos. | |
CO2022004684A2 (es) | Derivados de piridazin-3(2h)-ona fusionados con azol | |
CL2021000844A1 (es) | Compuestos de indolinona para uso como inhibidores de map4k1 | |
CL2022000955A1 (es) | Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1 | |
DOP2023000267A (es) | N-(hidroxialquil (hetero)aril) tetrahidrofurano carboxamidas como moduladores de canales de sodio | |
CO2022004723A2 (es) | Heteroaril bifenil amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1 | |
CR20190379A (es) | Moduladores del receptor de estrógeno | |
ECSP21080966A (es) | Derivados de 1,1-dióxido de 3-amino-4h-benzo[e][1,2,4] tiadiazina como inhibidores de mrgx2 | |
AR127050A1 (es) | Compuestos espirocíclicos | |
CO2022012884A2 (es) | Compuestos de amino pirimidina fusionados | |
UY39181A (es) | COMPUESTOS Y COMPOSICIONES PARA INHIBIR LA ACTIVIDAD DE HIF2a Y SUS MÉTODOS DE USO | |
CL2022002692A1 (es) | Derivados de n-(heterociclil y heterociclilalquil)-3-bencilpiridin-2-amina como agonistas de sstr4 | |
CO2022014423A2 (es) | Derivados de n-heteroarilalquil-2-(heterociclil y heterociclilmetil)acetamida como agonistas de sstr4 | |
ECSP22091230A (es) | Derivados de n-(piperidin-4-il)benzamida de acción luminal |